Sandy Draper
Stock Analyst at Guggenheim
(2.93)
# 1,438
Out of 4,853 analysts
119
Total ratings
58.33%
Success rate
19.74%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $293.58 | +47.15% | 12 | Jul 24, 2024 | |
IQV IQVIA Holdings | Downgrades: Neutral | n/a | $147.37 | - | 8 | Feb 15, 2024 | |
CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $141.20 | - | 15 | Feb 15, 2024 | |
EVH Evolent Health | Maintains: Hold | $36 → $34 | $8.19 | +315.14% | 9 | Nov 14, 2023 | |
GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $4.22 | +136.97% | 4 | Aug 10, 2023 | |
DOCS Doximity | Downgrades: Neutral | n/a | $57.34 | - | 3 | Aug 9, 2023 | |
TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $2.79 | -28.32% | 3 | Jun 16, 2023 | |
ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $134.82 | +95.07% | 13 | Apr 28, 2023 | |
AGL agilon health | Maintains: Buy | $21 → $30 | $2.10 | +1,328.57% | 3 | Mar 6, 2023 | |
HQY HealthEquity | Maintains: Buy | $89 → $94 | $112.70 | -16.59% | 11 | Dec 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $6.93 | - | 10 | Oct 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $22.80 | +123.73% | 2 | Aug 12, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $165.51 | -22.06% | 2 | May 25, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $26.98 | +103.85% | 2 | May 18, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $226 → $168 | $54.38 | +208.94% | 2 | May 12, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $52.77 | -77.26% | 1 | Apr 21, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $33 → $38 | $23.13 | +64.29% | 7 | Feb 4, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $5.06 | +888.14% | 1 | Jan 28, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $7.13 | +811.64% | 1 | Jan 28, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $3.84 | +837.50% | 4 | May 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $289.94 | -42.40% | 3 | Mar 26, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.47 | - | 2 | May 31, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $16.50 | +281.93% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $293.58
Upside: +47.15%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $147.37
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $141.20
Upside: -
Evolent Health
Nov 14, 2023
Maintains: Hold
Price Target: $36 → $34
Current: $8.19
Upside: +315.14%
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $4.22
Upside: +136.97%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $57.34
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $2.79
Upside: -28.32%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $134.82
Upside: +95.07%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $21 → $30
Current: $2.10
Upside: +1,328.57%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $112.70
Upside: -16.59%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $6.93
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $22.80
Upside: +123.73%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $165.51
Upside: -22.06%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $26.98
Upside: +103.85%
May 12, 2021
Maintains: Buy
Price Target: $226 → $168
Current: $54.38
Upside: +208.94%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $52.77
Upside: -77.26%
Feb 4, 2021
Maintains: Hold
Price Target: $33 → $38
Current: $23.13
Upside: +64.29%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $5.06
Upside: +888.14%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $7.13
Upside: +811.64%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $3.84
Upside: +837.50%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $289.94
Upside: -42.40%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.47
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $16.50
Upside: +281.93%